Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 30.0 Cr.
- Current Price ₹ 24.7
- High / Low ₹ 45.0 / 19.1
- Stock P/E
- Book Value ₹ 23.6
- Dividend Yield 0.00 %
- ROCE -10.7 %
- ROE -13.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.05 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 3.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 300 days.
- Working capital days have increased from 144 days to 223 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 25.27 | 38.19 | 22.63 | |
| 20.53 | 31.58 | 26.38 | |
| Operating Profit | 4.74 | 6.61 | -3.75 |
| OPM % | 18.76% | 17.31% | -16.57% |
| 1.07 | 0.10 | 0.08 | |
| Interest | 0.65 | 0.54 | 0.71 |
| Depreciation | 0.72 | 0.74 | 0.90 |
| Profit before tax | 4.44 | 5.43 | -5.28 |
| Tax % | 40.77% | 25.41% | -23.86% |
| 2.62 | 4.05 | -4.02 | |
| EPS in Rs | 3.05 | 3.46 | -3.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -199% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| Last Year: | -14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.70 | 12.17 |
| Reserves | 6.66 | 18.43 | 16.56 |
| 12.66 | 12.35 | 14.30 | |
| 10.52 | 16.73 | 8.60 | |
| Total Liabilities | 38.44 | 59.21 | 51.63 |
| 10.35 | 10.13 | 13.37 | |
| CWIP | 0.15 | 2.22 | 0.09 |
| Investments | 0.00 | 0.00 | 0.00 |
| 27.94 | 46.86 | 38.17 | |
| Total Assets | 38.44 | 59.21 | 51.63 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -3.66 | -4.54 | -4.60 | |
| -0.34 | -2.35 | -1.72 | |
| 4.01 | 10.47 | 3.48 | |
| Net Cash Flow | 0.01 | 3.58 | -2.83 |
| Free Cash Flow | -4.01 | -6.99 | -6.34 |
| CFO/OP | -73% | -67% | 119% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 241.21 | 247.06 | 300.32 |
| Inventory Days | 244.39 | 228.39 | 243.18 |
| Days Payable | 281.81 | 356.77 | 128.52 |
| Cash Conversion Cycle | 203.80 | 118.69 | 414.98 |
| Working Capital Days | 74.24 | 135.14 | 222.74 |
| ROCE % | 16.88% | -10.66% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Tablets Revenue Share % of total sales |
|
|||
| Government Contract Revenue Share % of total revenue |
||||
| Installed Capacity - Tablets Lakh tablets per year |
||||
| Number of Employees count |
||||
| Number of Products in Portfolio count |
||||
| Capacity Utilization % |
||||
| Number of Countries with Presence count |
||||
| Number of Customer Partners count |
||||
Extracted by Screener AI
Documents
Announcements
-
Resignation of Director/KMP/SMP
21 July 2026 - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP
-
Resignation of Director/KMP/SMP
21 July 2026 - Medicamen Organics Limited has informed about Resignation of Director/KMP/SMP
-
Cessation
21 July 2026 - Executive Director Brijesh Kumar Chaubey resigned effective July 20, 2026, citing family medical issues.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
9 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no demat/remat requests processed.
-
General Updates
9 June 2026 - Auditor certified ₹12.29 crore preferential allotment of 39 lakh shares and warrants on June 9, 2026.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.